Notable Clinical Benefit and Safety Data with IO-202 Plus Azacitidine in CMML

Written By Lara Wilson
Lara Wilson
Previous

IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia
Next

IO-202/Azacitidine Combo Provides Durable Responses in HMA-Naive CMML